Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa.

International journal of antimicrobial agents - 1 Feb 2006

Hansen Glen T, Zhao Xilin, Drlica Karl, Blondeau Joseph M

Abstract excerpt

The mutant prevention concentration (MPC) was determined by population analysis using six fluoroquinolone-susceptible isolates of Pseudomonas aeruginosa applied to fluoroquinolone-containing agar plates. The MPCs were 3 mg/L and 9.5 mg/L for ciprofloxacin and levofloxacin, respectively. At high concentrations of either compound, single-step gyrA resistance mutants were recovered. Using a modified method for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ciprofloxacin
Share to DNA Gyrase
Share to DNA Topoisomerase IV

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to Drug Resistance, Bacterial

Share to Levofloxacin

Share to Ofloxacin

Share to Pseudomonas aeruginosa

Source

Identifiers

PMID: 16426820
DOI: 10.1016/j.ijantimicag.2005.10.005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa.PMID 16426820Read ↗

Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.Semantic proximity Read ↗

Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa.Semantic proximity Read ↗

[Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration].Semantic proximity Read ↗

Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.Semantic proximity Read ↗

Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa.Semantic proximity Read ↗

Mutant prevention concentrations of levofloxacin, pazufloxacin and ciprofloxacin for A. baumannii and mutations in gyrA and parC genes.Semantic proximity Read ↗

[Mutant prevention concentrations of fluoroquinolones for Staphylococcus aureus].Semantic proximity Read ↗

Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.Semantic proximity Read ↗

Mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of Escherichia coli.Semantic proximity Read ↗

Mutant prevention concentrations of ciprofloxacin against urinary isolates of Escherichia coli and Klebsiella pneumoniae.Semantic proximity Read ↗

Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.Semantic proximity Read ↗

Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.